Dataset opportunity
Wallabymedical — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Wallabymedical, usable for Diagnostic AI and Computer Vision.
Score
42.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Imaging market = $1.6 billion in 2024, CAGR 23.2%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📣Press / announcement
Acquisition of phenox GmbH to expand neurointerventional portfolio and R&D capabilities
source ↗ - 🤝Data partnership
Exclusive 10-year distribution and data-sharing agreement with Japan Lifeline
source ↗ - ✨Signal
FDA 510k Clearance for pRESET Thrombectomy Device involving clinical validation data
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Wallabymedical holds a proprietary Medical Imaging Dataset derived from its R&D in patented neurovascular technologies. This high-quality collection, substantiated by industrial data, medical records, and regulatory evidence, is exceptionally suited for training and validating Diagnostic AI models, particularly in complex neurological applications like stroke detection and aneurysm analysis.
This data is a key asset in the global AI in Medical Imaging market, a sector valued at $1.6 billion in 2024 and projected to grow at a 23.2% CAGR. [1] Despite access complexities due to highly regulated medical data (HIPAA/GDPR compliance), shared clinical trial ownership, and its link to proprietary R&D, the rarity and specificity of this neurovascular dataset offer a significant competitive advantage for developing next-generation AI diagnostic tools. [1] ⚠ Diligence (valuable data, access to negotiate): Highly regulated medical data requiring HIPAA/GDPR compliance; Clinical trial data ownership may involve hospital partners; Proprietary R&D data linked to patented neurovascular technologies · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Wallabymedical possesses a proprietary dataset of neurovascular imaging data generated from its own clinically validated medical devices. This data is essential for training high-performance diagnostic AI models, a market currently valued at $1.6 billion and growing rapidly. The dataset's value is significantly enhanced by its lineage from devices with global regulatory approval, suggesting a unique combination of quality, scale, and geographic diversity that is difficult to replicate.
See dimension details ↓- Buyer Demand90
High buyer demand is driven by the urgent need for high-quality, specialized data to compete in the AI in Medical Imaging market, which is expanding at a 23.2% CAGR. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation73
3 data-appetite signals (3 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit42
⚠ review — Wallaby Medical's core business is developing and selling medical devices for stroke treatment, and it also distributes third-party AI imaging software, making it a vendor already on the market, not a source of dormant data. Issues: Company's core business is selling medical devices (hardware), not a service that generates data as a byproduct. [3, 5, 7, 8]; Company actively sells/distributes AI software for stroke imaging analysis as part of its product suite, which is an intelligence product. [2, 16]; Following its ~€500 million acquisition of Phenox GmbH, the company has over 700 employees and a global presence, bordering on being a large enterprise rather t; The company's privacy policy mentions collecting usage data, but this appears to be for website analytics and service improvement, not a distinct, proprietary d
- Deep Qualification70
✓ pass — Wallaby Medical is a tooling vendor that manufactures and sells neurovascular devices. It generates proprietary data through extensive R&D and clinical trials, but ownership is likely mixed with trial partners and the data is highly regulated. The inability to access legal terms makes licensing rights unclear.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence confirms the dataset originates from devices that have secured regulatory approval in major global markets, providing AI developers with high-quality, clinically validated imaging data for building trustworthy diagnostic tools.
Industrial data
This indicates a large and sophisticated operation with a complete product portfolio, suggesting the dataset is not a one-off collection but a scalable, ongoing stream of data with significant potential for scale and variety.
Regulatory records
This proves the underlying devices have achieved global distribution across more than 60 countries, ensuring the resulting dataset reflects diverse populations from key markets like the US, EU, and Asia, which is critical for developing robust and unbiased AI models.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Wallabymedical Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market = $1.6 billion in 2024, CAGR 23.2% (source: MarketsandMarkets Analysis). [1]. Investment score 42.5/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Qosina — Industrial Operations Dataset Opportunity
View opportunity →healthcareSutter Med — Medical Imaging Dataset Opportunity
View opportunity →healthcareBiossusa — Image Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- Is Your Data Worth Money?3 min read
- What is a Dataset Worth?3 min read
- How a Data Transaction Works3 min read